[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-344877-en":59,"doc-seo-344877-105":97},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":72,"language_code":73,"site_id":74,"html_lang":73,"table_of_contents":75,"faqs":76,"seo_title":77,"seo_description":66,"update_tm":78,"read_time":46,"preview_page_count":19,"preview_urls":79},344877,1649267921044,"Ava Thompson","https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","The changing landscape of urothelial carcinoma: on the edge of a paradigm shift","Reviewing urothelial cancers of the urinary tract, the article highlights shifting patient demographics, including more younger patients and increasing incidence in females. It summarizes paradigm-shifting clinical trials across disease stages, emphasizing new therapeutics and drug-delivery options for non–muscle-invasive bladder cancer approvals. For muscle-invasive disease, chemotherapy, immunotherapy, and antibody-drug conjugates are reshaping perioperative care. It also discusses liquid biomarkers such as circulating and urinary tumor DNA to stratify recurrence risk, potentially enabling bladder-sparing strategies without bladder removal.","The Journal of Clinical Investigation REVIEW  \nThe changing landscape of urothelial carcinoma: on the edge of a paradigm shift  \nJoshua J. Meeks1,2,3  \n1Departments of Urology and 2Biochemistry and Molecular Genetics, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. 3Jesse Brown VA Medical Center, Department of Veterans Affairs, Chicago, Illinois, USA.  \nUrothelial cancers ofthe urinary tract are the fourth most common malignancy in men, with a shifting demographic affecting younger patients and an increasing incidence in females. In this Review, we discuss recent discoveries and paradigm-shifting clinical trials that impact all stages of urothelial cancer. New therapeutics and drug-delivery devices have led to multiple approvals for treatments of non-muscle invasive bladder cancer. The addition of chemotherapy, immunotherapy, and antibody-drug conjugates is transforming perioperative treatment for patients with muscle-invasive bladder cancer. The use of liquid biomarkers, circulating tumor DNA, and urinary tumor DNA is aiding the identification of patients at risk for local recurrence and possibly those who can avoid systemic therapy. Finally, integrating biomarkers and systemic treatments is creating a paradigm that could lead to the successful treatment of bladder cancer without requiring bladder removal. Overall, these advancements in biomarkers and novel therapeutics are likely to dramatically improve survival for bladder cancer.  \nIntroduction  \nUrothelial carcinoma comprises epithelial tumors of the urinary tract: the renal pelvis and ureter (15% of cases; upper urinary tract), the bladder (80% of cases; lower urinary tract), and the urethra (5%, including the prostatic urethra to the meatus) (1) . Bladder cancer is the fourth most common cancer in men in the United States and is the tenth most common worldwide across sexes (2, 3) . In the United States alone, over 84,000 new cases are diagnosed each year, and more than 744,000 people are living with bladder cancer (4) . Although bladder cancer has historically occurred with a 3:1 male predominance, we are observing a demographic shift: a 1% annual decrease in male incidence in many parts of Europe, along with a significant trend toward earlier diagnosis in patients under 50 years old (hazard ratio [HR] 1.34, 95% CI 0 .6–2.07, P = 0.003) (2) . Bladder cancer was once primarily considered a smoking-related cancer; however, unlike lung cancer, only 50% of bladder cancer patients have a history of smoking, and the direct correlation between pack-years and mutation rate is nonlinear (5) . Moreover, while the incidence and mortality rates of lung cancer have decreased due to smoking cessation and screening, comparable improvements have not been observed in bladder cancer (4) . The persistent incidence and steady mortality suggest that the mechanisms of carcinogenesis in bladder cancer may differ from those in lung cancer and are likely independent of smoking (6) . In the absence of a clear etiology and effective strategies to screen high-risk  \nConflict of interest: JJM has received consulting or speaking fees from Merck, AstraZeneca, Janssen, Bristol Myers Squibb, UroGen, Prokarium, Imvax, Pfizer, Seagen/ Astellas, Ferringn Pharmaceuticals, CG Oncology, Immunity Bio, Protara Therapuetics, and Photocure.  \nCopyright: © 2026, Meeks et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.  \nReference information: J Clin Invest. 2026;136(5):e202079 .  \n[https://doi.org/10.1172/JCI202079](https://doi.org/10.1172/JCI202079) .  \nyet asymptomatic patients, future advances in bladder cancer are likely to depend on new therapeutics and biomarkers for patient selection (7) . This Review emphasizes innovative paradigms, emerging technologies, and targeted treatments that are rapidly transforming the landscape of bladder cancer.  \nEarly-stage cancer: novel therapies  \nAlmost 75% of bladder","cbCaitiDd72vDias","https://ap.wps.com/l/cbCaitiDd72vDias","pdf",1114786,"English","en",105,"# Introduction\n# Early-stage cancer: novel therapies","[{\"question\":\"How does the article describe recent demographic changes in urothelial cancer patients?\",\"answer\":\"It notes a shifting demographic, including decreasing male incidence in parts of Europe and a trend toward earlier diagnosis in patients under 50, along with increasing incidence in females.\"},{\"question\":\"What treatments are emphasized for non–muscle-invasive bladder cancer?\",\"answer\":\"The review emphasizes new therapeutics and drug-delivery devices, including multiple approvals and the role of topical therapies across the urothelium, with BCG highlighted as the oldest widely used therapy.\"},{\"question\":\"Which biomarkers does the review discuss for patient selection and recurrence risk?\",\"answer\":\"It discusses liquid biomarkers, specifically circulating tumor DNA and urinary tumor DNA, to identify patients at risk for local recurrence and to help determine who may avoid systemic therapy.\"}]","The changing landscape of urothelial carcinoma: on the edge of a paradigm shift | PDF",1790055523,[80,84,88,93],{"page_no":8,"url":81,"width":82,"height":83},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/763e6f49a78bd0f640221073cec9972e.webp",983,1315,{"page_no":14,"url":85,"width":86,"height":87},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61e511e3bca65a45b14dfb7297c1fff3.webp",982,1314,{"page_no":89,"url":90,"width":91,"height":92},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b811b3b9fb85e388629057ff13064e46.webp",981,1312,{"page_no":19,"url":94,"width":95,"height":96},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8200ec01b15ecc40470cbda75089d0f7.webp",980,1311,{"code":4,"msg":98,"data":99},"ok",{"site_id":74,"language":73,"slug":100,"title":65,"keywords":101,"description":66,"schema_data":102,"social_meta":155,"head_meta":157,"extra_data":159,"updated_unix":160},"the-changing-landscape-of-urothelial-carcinoma-on-the-edge-of-a-paradigm-shift","",{"@graph":103,"@context":154},[104,117,137],{"@type":105,"itemListElement":106},"BreadcrumbList",[107,111,113,115],{"item":108,"name":109,"@type":110,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":112,"name":9,"@type":110,"position":14},"https://docshare.wps.com/document/",{"item":114,"name":40,"@type":110,"position":89},"https://docshare.wps.com/document/research-report/",{"item":116,"name":65,"@type":110,"position":19},"https://docshare.wps.com/document/the-changing-landscape-of-urothelial-carcinoma-on-the-edge-of-a-paradigm-shift/344877/",{"url":116,"name":65,"@type":118,"image":119,"author":124,"headline":65,"publisher":126,"fileFormat":129,"inLanguage":73,"description":66,"dateModified":130,"datePublished":131,"encodingFormat":129,"isAccessibleForFree":132,"interactionStatistic":133},"DigitalDocument",{"url":120,"@type":121,"width":122,"height":123},"https://docshare.wps.com/thumbnails/the-changing-landscape-of-urothelial-carcinoma-on-the-edge-of-a-paradigm-shift/344877.png","ImageObject",300,407,{"name":63,"@type":125},"Person",{"url":108,"name":127,"@type":128},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":134,"interactionType":135,"userInteractionCount":34},"InteractionCounter",{"@type":136},"ViewAction",{"@type":138,"mainEntity":139},"FAQPage",[140,146,150],{"name":141,"@type":142,"acceptedAnswer":143},"How does the article describe recent demographic changes in urothelial cancer patients?","Question",{"text":144,"@type":145},"It notes a shifting demographic, including decreasing male incidence in parts of Europe and a trend toward earlier diagnosis in patients under 50, along with increasing incidence in females.","Answer",{"name":147,"@type":142,"acceptedAnswer":148},"What treatments are emphasized for non–muscle-invasive bladder cancer?",{"text":149,"@type":145},"The review emphasizes new therapeutics and drug-delivery devices, including multiple approvals and the role of topical therapies across the urothelium, with BCG highlighted as the oldest widely used therapy.",{"name":151,"@type":142,"acceptedAnswer":152},"Which biomarkers does the review discuss for patient selection and recurrence risk?",{"text":153,"@type":145},"It discusses liquid biomarkers, specifically circulating tumor DNA and urinary tumor DNA, to identify patients at risk for local recurrence and to help determine who may avoid systemic therapy.","https://schema.org",{"og:url":116,"og:type":156,"og:title":65,"og:site_name":127,"og:description":66},"article",{"robots":158,"canonical":116},"index,follow",{"doc_id":61,"site_id":74},1790501129]